NCT05660421 2024-10-31
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
Clinical Trials
17 trialsNCT05288595 2024-10-18
TCR Alpha/Beta and CD19-deplete Haplo-HSCT
University of Colorado, Denver
Phase 2 Withdrawn
NCT04282174 2022-09-27
2019-KOE-001
Baptist Health South Florida
Phase 2 Withdrawn
NCT04138875 2022-06-23
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Yale University
Phase 2 Withdrawn
NCT04455958 2021-04-26
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT04127721 2020-10-29
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04392128 2020-09-04
HYACINTHE
Institut de cancérologie Strasbourg Europe
Phase 2 Withdrawn
NCT04439305 2020-07-20
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT04016116 2020-05-27
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
NYU Langone Health
Phase 2 Withdrawn
NCT01479582 2018-12-21
Providing Access to Cord Blood Units for Transplants
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT02718755 2018-06-26
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02118311 2017-12-02
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT02343679 2017-02-01
Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
Duke University
Phase 2 Withdrawn
NCT01554254 2016-08-31
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation
Tarix Pharmaceuticals
Phase 2 Withdrawn
NCT01882387 2016-08-31
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Tarix Pharmaceuticals
Phase 2 Withdrawn
NCT01131247 2011-07-20
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Nevada Cancer Institute
Phase 2 Withdrawn
NCT00149032 2011-04-08
Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host
Hadassah Medical Organization
Phase 2 Withdrawn